MOTHAFFAR RIMAWI to Pyridines
This is a "connection" page, showing publications MOTHAFFAR RIMAWI has written about Pyridines.
Connection Strength
0.237
-
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4870-4882.
Score: 0.160
-
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2- Breast Cancer. Clin Cancer Res. 2022 01 01; 28(1):163-174.
Score: 0.042
-
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. J Clin Oncol. 2019 01 20; 37(3):178-189.
Score: 0.034